UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000003669
Receipt number R000004448
Scientific Title Clinical research for hemoperfusion therapy with an immobilized polymyxin B (PMX) fiber column in patients with severe influenza pneumonia in Vietnam and Japan
Date of disclosure of the study information 2010/05/27
Last modified on 2019/03/27 20:57:21

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Clinical research for hemoperfusion therapy with an immobilized polymyxin B (PMX) fiber column in patients with severe influenza pneumonia in Vietnam and Japan

Acronym

Clinical research for hemoperfusion therapy in patients with severe influenza pneumonia

Scientific Title

Clinical research for hemoperfusion therapy with an immobilized polymyxin B (PMX) fiber column in patients with severe influenza pneumonia in Vietnam and Japan

Scientific Title:Acronym

Clinical research for hemoperfusion therapy in patients with severe influenza pneumonia

Region

Japan Asia(except Japan)


Condition

Condition

severe influenza pneumonia

Classification by specialty

Pneumology Infectious disease Intensive care medicine

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

This clinical research is aimed to investigate the efficacy of direct hemoperfusion (DHP) with an immobilized polymyxin B (PMX) fiber column (PMX-DHP) in patients with severe influenza pneumonia in Vietnam and Japan.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Explanatory

Developmental phase



Assessment

Primary outcomes

survival

Key secondary outcomes

serial changes in blood test, levels of inflammatory mediators, physical findings and radiolgical images


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Device,equipment Maneuver

Interventions/Control_1

Blood purification therapy

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

(1) Infection with influenza A virus is suspected.
The definitive diagnosis is made when the specimens obtained from the patient are A positive by Polymerase Chain Reaction (PCR) method or rapid test kit.
(2) The patient with moderate or severe pneumonia.
1) New infiltration lesion detected on the first CXR or newly occurred among the film series.
2) The patient who fulfills PaO2/FiO2 ratio of 80-300.
(3) The patient whose symptom onset is no later than 7 days.
(4) The patient from whom (or whose deputy) a written consent is obtained.

Key exclusion criteria

(1) Individuals who do not meet the above mentioned criteria for cases.
(2) Individuals who do not agree to sign the informed consents.
(3) Individuals with Immune deficiency.
(4) Individuals who are decided to be NOT suitable for this research by a clinical doctor.

Target sample size

10


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Koichiro Kudo

Organization

National Center for Globsl Health and Medicine

Division name

Disease Control and Prevention Center

Zip code


Address

1-21-1 Toyama, Shinjuku-Ku, Tokyo, Japan

TEL


Email



Public contact

Name of contact person

1st name
Middle name
Last name Jin Takasaki

Organization

National Center for Globsl Health and Medicine

Division name

Disease Control and Prevention Center/Departmant of Respiratory Medicine

Zip code


Address


TEL

0332027181

Homepage URL


Email

jin@dcc.go.jp


Sponsor or person

Institute

Disease Control and Prevention Center

Institute

Department

Personal name



Funding Source

Organization

Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan

Organization

Division

Category of Funding Organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2010 Year 05 Month 27 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2008 Year 02 Month 14 Day

Date of IRB

2008 Year 02 Month 01 Day

Anticipated trial start date

2008 Year 02 Month 01 Day

Last follow-up date

2014 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2010 Year 05 Month 27 Day

Last modified on

2019 Year 03 Month 27 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000004448


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name